January
Thursday 8 March 2018 photo 15/30
|
Methylphenidate monitoring guidelines: >> http://xzn.cloudz.pw/download?file=methylphenidate+monitoring+guidelines << (Download)
Methylphenidate monitoring guidelines: >> http://xzn.cloudz.pw/read?file=methylphenidate+monitoring+guidelines << (Read Online)
Methylphenidate for ADHD in children and adolescents - shared care guideline. Version 3. Principal Dosage and administration: Methylphenidate immediate release tablets are first choice treatment. Ensure baseline monitoring of height, weight, BP has been performed plus any additional relevant investigations.
Date approved: DPC March 2017. Review date: March 2019. Shared Care Guideline for Methylphenidate, Atomoxetine, Dexamfetamine &. Lisdexamfetamine for ADHD in Children and Adolescents (GP Summary). It is essential that a transfer of care only takes place with agreement of the GP and when sufficient information.
Patients for whom methylphenidate treatment is deemed appropriate should be carefully monitored as follows: Blood pressure should be recorded at every dose adjustment and then at least every six months; pulse should also be recorded. Height, weight and appetite should be recorded at least every six months.
24 Sep 2008 Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about 1.8.4.9 For children and young people taking methylphenidate and dexamfetamine, healthcare professionals and parents or carers should monitor
22 Mar 2006 Evidence-based recommendations on methylphenidate, atomoxetine and dexamfetamine for treating ADHD in children and young people. This guidance replaces NICE technology appraisal guidance 13. Guidance development process. How we develop NICE technology appraisal guidance
28 Jun 2016 Methylphenidate MR tablets eg: Concerta® XL Tablets and other equivalent. (branded) generic MR tablet preparations: 18mg once daily, after breakfast, increased if necessary at weekly intervals by 18mg. Max recommended dose 108mg daily in adults with close monitoring. Max licensed dose is 54mg
NICE (March 2006). Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents; Drug and Therapeutics Bulletin (2001), 39 (7), 52-54. NICE (October 2000). Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention Deficit / Hyperactivity
SHARED CARE GUIDELINES FOR THE PRESCRIBING OF METHYLPHENIDATE IN. ATTENTION The guideline states that “drug treatment is the first-line treatment for adults with ADHD with either moderate or that following titration and dose stabilisation, prescribing and monitoring should be carried out under locally
consultant if the monitoring programme is not complied with (and informing the GP in writing if appointments are not kept). – Appendix 1 section 6 of prescribing guidelines. 6. Liaising with the GP to agree to share the patients care after the final therapeutic dose and benefit from treatment is established (usually after 3-6
These guidelines aim to provide a framework for the prescribing of methylphenidate by The guidelines should be read in conjunction with . Monitoring. Pre-treatment evaluation. Before starting drug treatment, children and young people with ADHD should have a full pre-treatment assessment which should include:.
Annons
Visa toppen
Show footer